DSIP (Delta Sleep-inducing Peptide)

Last Updated: August 2026

DSIP (Delta Sleep-Inducing Peptide), also designated Emideltide, is a nine-amino-acid neuropeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood during slow-wave sleep induction. It is researched for sleep regulation, stress adaptation, and normalization of disturbed sleep architecture, with mechanism remaining incompletely characterized despite decades of research. DSIP is not approved by major Western regulators. Important regulatory update: DSIP (Emideltide) was removed from the FDA's Category 2 bulk substances list on April 22, 20261 source and was reviewed by the FDA's Pharmacy Compounding Advisory Committee on July 23–24, 2026 — where DSIP was the only compound the committee voted against recommending for the 503A compounding list (6–7 with one abstention).1 source

What is DSIP and how does the sleep-modulation mechanism work?

DSIP is a nine-amino-acid neuropeptide isolated in the 1970s from the cerebral venous blood of rabbits during sleep-induction experiments, with the nonapeptide itself characterized in 1977 by Schoenenberger and Monnier1 source during electrically-induced slow-wave sleep, named for its ability to induce delta-frequency EEG activity associated with deep sleep. Despite decades of research, the precise molecular mechanism remains incompletely characterized — proposed mechanisms include modulation of multiple neurotransmitter systems (GABA, serotonin), HPA axis effects, and direct EEG-influencing effects through poorly-defined receptor mechanisms. Endogenous DSIP-like activity has been documented in human plasma. Evidence level: Preclinical extensive (sleep architecture, stress effects); limited human clinical research; mechanism incompletely characterized.

What does the research show for DSIP?

Preclinical and limited human research has explored DSIP for sleep architecture normalization in insomnia, stress adaptation, and alcohol withdrawal contexts. Effects on sleep latency, sleep efficiency, and slow-wave sleep duration have been reported with varied magnitude across studies. The compound has not advanced to formal Phase 2/3 pharmaceutical development by any The human record is thin and old: small studies from the late 1970s and 1980s, mostly from the groups that discovered the peptide. The most-cited positive result — a 1981 Lancet report that synthetic DSIP improved sleep in insomniacs — was small and short-term,1 source follow-up controlled studies reported improvements on some sleep measures but not others, and the effects never consolidated into a reproducible clinical signal.1 source Two decades later, a 2006 review could still describe DSIP's identity and physiological role as "a still unresolved riddle" — no gene or receptor for it has been identified.1 source research base is academic and exploratory rather than industry-sponsored sponsor; the research base is academic and exploratory rather than industry-sponsored. Evidence level: Preclinical (multiple sleep models); limited human research; no formal Phase 2/3 development.

How does DSIP compare to other sleep-related peptides?

DSIP occupies a distinct niche in sleep-research compounds — endogenous origin, neuropeptide structure, focus on sleep architecture rather than direct sedation. Unlike sedative-hypnotics or melatonin-pathway compounds, DSIP's proposed mechanism is sleep-architecture normalization rather than sleep induction.

What are the documented side effects of DSIP?

Side effects in available research use are generally mild — occasional mild stimulation effects (paradoxical given the sleep-related mechanism), transient headache, and injection-site reactions. The endogenous origin and limited systemic effects support a favorable inherent safety profile. Long-term safety in humans at sustained research-use dosing is not characterized at Western RCT standards. Evidence level: Preclinical safety; limited human safety; long-term unestablished.

What is the regulatory status of DSIP?

DSIP (also Emideltide) is not approved for any medical indication anywhere in the world as of August 2026. On April 22, 2026, DSIP/emideltide came off the FDA’s Category 2 bulk-substances list — one of 12 peptides removed because, in FDA’s words, their nominations were withdrawn by the nominators; removal did not authorize compounding or place DSIP on any approved list.1 source At the FDA’s Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026, DSIP was the sole rejection: the committee voted 6–7 (one abstention) against recommending it for the 503A compounding list, while recommending the other six peptides reviewed. The vote is advisory — FDA staff had opposed all seven nominations, no decision is final, and formal rulemaking is not expected before 2027 — but it leaves DSIP with no active pathway toward legal compounding as of August 2026.1 source Removal from Category 2 does not authorize compounding — formal Category 1 inclusion or 503A bulks list addition remains pending PCAC determination. Current status in FDA peptide regulation 2025–2026 timeline.

Why does DSIP vendor verification matter?

DSIP synthesis is mature and broadly available, but the nine-amino-acid sequence shares amino acid composition patterns with related neuropeptides — mass spectrometry identity confirmation is important. The compound is relatively niche, with fewer vendors and varied quality control across the available market. Independent HPLC purity testing and mass spectrometry are the standard quality signals. Guidance in how-to-test-peptides hub.

How does Peptigrity verify DSIP vendors?

Peptigrity collects independent third-party Certificates of Analysis for DSIP from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently Asked Questions

What does DSIP do?

DSIP is researched for sleep architecture normalization — particularly increasing slow-wave (delta) sleep — and for stress adaptation effects. The precise mechanism remains incompletely characterized despite decades of research. Human clinical evidence is more limited than the preclinical base.

Is DSIP legal to purchase?

DSIP (Emideltide) is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. The April 22, 2026 Category 2 removal (the nomination was withdrawn by the nominators) did not authorize compounding, and in July 2026 the FDA's advisory committee voted against recommending DSIP for the 503A compounding list — so a legal compounding pathway now looks unlikely in the near term.1 source Country breakdown in peptide legal status guide.

When will the FDA decide on DSIP?

The advisory step already happened — and went against DSIP. At its July 23–24, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted 6–7 (one abstention) against recommending DSIP/emideltide for the 503A compounding list — the only compound rejected at that meeting.1 source The vote is advisory: FDA has not issued a final rule, and formal rulemaking is not expected before 2027. Until then DSIP remains a research chemical with no approved use and no compounding pathway. Track developments in FDA peptide regulation 2025–2026 timeline.

How does DSIP compare to melatonin or sleep medications?

DSIP's proposed mechanism is sleep architecture normalization through poorly-characterized neuropeptide pathways — different from melatonin (circadian rhythm signaling) or GABA-A-targeted sleep medications (direct sedation). None of these are mechanistically interchangeable.

How can I verify a DSIP vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a DSIP dose?

No. DSIP is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies. Anyone considering use should consult a licensed physician — particularly for sleep concerns where evidence-based options exist.

This section is for educational and informational purposes only and does not constitute medical advice. This section is for educational and informational purposes only and does not constitute medical advice. DSIP (emideltide) is not approved by the FDA or equivalent regulators for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.